Paper34576141
Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y and 13 others. Int J Mol Sci, 2021. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. Papers, record 34576141. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34576141
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain Neoplasms | Major topic |
| Glioblastoma | Major topic |
| Killer Cells, Natural | Major topic |
| Lymphocyte Activation | Major topic |
| Animals | |
| Apoptosis | |
| B7-H1 Antigen | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Cytokines | |
| Mice | |
| Mice, Inbred NOD | |
| Mice, SCID | |
| Natural Cytotoxicity Triggering Receptor 1 | |
| Programmed Cell Death 1 Receptor | |
| Subcutaneous Tissue | |
| Survival Analysis |
Source PubMed
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22394507 | Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. | Exp Cell Res | 2012 | https://conductscience.org/library/papers/22394507 | PubMed |
| 2 | 28955340 | The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. | Front Immunol | 2017 | https://conductscience.org/library/papers/28955340 | PubMed |
| 3 | 10684858 | Differential tumor surveillance by natural killer (NK) and NKT cells. | J Exp Med | 2000 | https://conductscience.org/library/papers/10684858 | PubMed |
| 4 | 9798907 | Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. | J Neurochem | 1998 | https://conductscience.org/library/papers/9798907 | PubMed |
| 5 | 26323609 | PD-L1 expression and prognostic impact in glioblastoma. | Neuro Oncol | 2016 | https://conductscience.org/library/papers/26323609 | PubMed |
| 6 | 27662664 | PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27662664 | PubMed |
| 7 | 7366733 | Role of NK cells in tumour growth and metastasis in beige mice. | Nature | 1980 | https://conductscience.org/library/papers/7366733 | PubMed |
| 8 | 15032583 | The dynamic life of natural killer cells. | Annu Rev Immunol | 2004 | https://conductscience.org/library/papers/15032583 | PubMed |
| 9 | 22639163 | Adoptive cell transfer therapy for malignant gliomas. | Adv Exp Med Biol | 2012 | https://conductscience.org/library/papers/22639163 | PubMed |
| 10 | 30840664 | Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. | PLoS One | 2019 | https://conductscience.org/library/papers/30840664 | PubMed |
| 11 | 29354116 | Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. | Front Immunol | 2017 | https://conductscience.org/library/papers/29354116 | PubMed |
| 12 | 9670929 | Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. | J Immunol | 1998 | https://conductscience.org/library/papers/9670929 | PubMed |
| 13 | 9486650 | HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. | Nature | 1998 | https://conductscience.org/library/papers/9486650 | PubMed |
| 14 | 32437507 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32437507 | PubMed |
| 15 | 21508954 | Retro-orbital injections in mice. | Lab Anim (NY) | 2011 | https://conductscience.org/library/papers/21508954 | PubMed |
| 16 | 23377437 | Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. | Blood | 2013 | https://conductscience.org/library/papers/23377437 | PubMed |
| 17 | 17100888 | The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. | Immunol Rev | 2006 | https://conductscience.org/library/papers/17100888 | PubMed |
| 18 | 32487617 | KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells. | Anticancer Res | 2020 | https://conductscience.org/library/papers/32487617 | PubMed |
| 19 | 29861604 | Tumor immunotherapy: New aspects of natural killer cells. | Chin J Cancer Res | 2018 | https://conductscience.org/library/papers/29861604 | PubMed |
| 20 | 20536569 | Effect of NKG2D ligand expression on host immune responses. | Immunol Rev | 2010 | https://conductscience.org/library/papers/20536569 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42658392 | From liver to cardiovascular system: the MASLD-ASCVD continuum. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/42658392 | PubMed |
| 42375809 | Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances. | Mil Med Res | 2026 | https://conductscience.org/library/papers/42375809 | PubMed |
| 41601660 | Natural killer cell-based senotherapy: a promising strategy for healthy aging. | Front Immunol | 2025 | https://conductscience.org/library/papers/41601660 | PubMed |
| 41346595 | Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41346595 | PubMed |
| 41144130 | The microenvironment of glioblastoma: in pursuit of universal multimodal immunotherapy. | Acta Neurol Belg | 2026 | https://conductscience.org/library/papers/41144130 | PubMed |
| 38397112 | Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38397112 | PubMed |
| 38130720 | ROS regulation in gliomas: implications for treatment strategies. | Front Immunol | 2023 | https://conductscience.org/library/papers/38130720 | PubMed |
| 37841273 | Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro. | Front Immunol | 2023 | https://conductscience.org/library/papers/37841273 | PubMed |
| 37762486 | Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762486 | PubMed |
| 37303464 | An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood. | Regen Ther | 2023 | https://conductscience.org/library/papers/37303464 | PubMed |
| 37240104 | Natural Killer Cells and Immunotherapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37240104 | PubMed |
| 36792722 | Advances in NK cell therapy for brain tumors. | NPJ Precis Oncol | 2023 | https://conductscience.org/library/papers/36792722 | PubMed |
| 36768432 | Natural Killer Cell-Based Immunotherapy against Glioblastoma. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768432 | PubMed |
| 35919498 | Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. | Regen Ther | 2022 | https://conductscience.org/library/papers/35919498 | PubMed |
| 35203609 | The War Is on: The Immune System against Glioblastoma-How Can NK Cells Drive This Battle? | Biomedicines | 2022 | https://conductscience.org/library/papers/35203609 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34576141
GET https://conductscience.org/api/papers/v1/34576141/references?page=2